Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of subcutaneous lunsekimig in adults with moderate-to-severe asthma after DRI16762
MOH_2024-10-15_013697Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lunsekimig in asthma, sponsored by Sanofi. Primary endpoint: Long-term safety of lunsekimig. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on MOH_2024-10-15_013697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-10-15_013697.